Lv5
900 积分 2025-12-15 加入
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
13天前
已完结
Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients
24天前
已完结
B cell checkpoints in autoimmune rheumatic diseases
29天前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
The dawn of ‘off-the-shelf’ B cell-depleting therapies for autoimmune diseases
1个月前
已完结
Roads and detours for CAR T cell therapy in autoimmune diseases
1个月前
已完结
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
1个月前
已完结
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma
1个月前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
1个月前
已完结
皖公网安备34019202002308
